

MP3 Initiative Seed Grants Awards

2019 See	d Grants (Award Start - 1/1/20)
Project Title: The sum of the parts: Understanding the interaction between individual and population immunity to dengue, viral diversity, and transmissiondynamics Research Team Matthew Collins, MD, PhD (PI; Assistant Professor; SOM) Anne Piantadosi, MD, PhD (Assistant Professor; SOM) Gonzalo Vazquez-Prokopec, PhD (Associate Professor; ECAS) <u>Award Total</u> : \$250,000 over 2 years	Abstract: This project leverages existing and newly generated data on virus, vector, and host in the frame of Ecological Immunology to comprehensively define dengue virus transmission dynamics. Viruses circulating in mosquito and humans over the time span of a decade will be characterized by next generation sequencing and phylogenetics. Simultaneously, neutralizing antibody responses will be defined at individual and population levels. Results will be integrated with existing epidemiologic data to generate a dengue susceptibility map that predicts novel strain introduction. The model will be validated by historical and prospective dengue surveillance, providing an invaluable tool for high priority public health activities.
 <u>Project Title:</u> Microbiome organisms and natural immunity against pneumococcal disease <u>Research Team</u> <u>Cynthia G. Whitney, MD (Professor, RSPH)</u> Nadine Rouphael, MD (Associate Professor, SOM) Jesse J. Waggoner, MD (Assistant Professor, SOM) <u>Award Total</u>: \$250,000 over 2 years 	<u>Abstract</u> : Pneumococcal disease is a leading cause of illness and death, especially among the elderly in all countries and young children in low-income settings. How humans develop natural immunity to the range of pneumococcal serotypes is unknown. We plan to evaluate whether the presence of encapsulated Streptococcal bacteria that are part of the upper respiratory tract microbiome is associated with antibodies that could protect against invasive pneumococcal strains. If so, these commensal organisms could boost vaccine-induced or natural immunity in highly vulnerable populations, such as those in sub-Saharan Africa, where pneumococcal disease is not well controlled in spite of immunization programs.

2020 Seed	Grants continued (Award Start – 9/1/20)
 <u>Project Title</u>: Characterizing the extent and epidemiological impact of hybrid schistosomes in Tanzania. <u>Research Team</u> David Civitello, PhD (Assistant Professor, ECAS) Matthew Freeman, PhD; (Associate Professor, RSPH) <u>Award Total</u>: \$199,720 over 2 years 	<u>Abstract</u> : Human schistosomes, blood flukes transmitted via freshwater snails, impose major, yet neglected human morbidity globally. Transmission occurs in ecologically complex communities and anintegrative multiscale approach is needed to evaluate the drivers of transmission, develop tools for surveillance, and disrupt transmission. Recent documentation of naturally occurring hybrid schistosomes, arising from cattle- and human- specialists, overturns conventional wisdom and challenges existing control measures. Hybrids are more virulent and infectious than the parental species and can backcross and persist in humans. We will characterize the prevalence and distribution of human-cattle hybrid schistosomes, identify their drivers, and assess their relevance for schistosome eradication.
Project Title: Integration of human contact and mobility data with infection history for models of infectious disease transmission.Research TeamBenjamin Lopman, PhD (Professor, RSPH) Ymir Vigfusson, PhD (Assistant Professor, ECAS) Jan Vinjé, PhD, (PI, CDC) Kristin Nelson, PhD (Assistant Professor, RSPH)Award Total:\$250,000 over 2 years	<u>Abstract</u> : Patterns of human contact in households, in communities, and across regions determine how infectious diseases spread and modulate the impact of control measures. However, our understanding of how human contact and mobility shape disease risk is limited. Our goal is to develop a new platform that will integrate human contact and mobility data with infection history to build tractable, realistic models of disease transmission. We will demonstrate the range and utility of this platform by modeling (1) geographic variation in rotavirus incidence post-vaccine introduction and (2) social distancing and travel restrictions to reduce spread ofSARS-CoV-2.
 <u>Project Title</u>: Characterizing molecular regulation of Acinetobacter baumannii phenotypes to understand its spread dynamics in a host community. <u>Research Team</u>: <u>Minsu Kim, PhD (Associate Professor, ECAS)</u> Phil Rather, PhD (Professor, SOM) Daniel Weissman, PhD (Assistant Professor, ECAS) Nic Vega, PhD (Assistant Professor, ECAS) <u>Award Total</u>: \$300,000 over 2 years 	<u>Abstract</u> : Acinetobacter baumannii is responsible for numerous outbreaks across the globe. Recently, it emerged as one of the most serious threats due to the prevalence of antibiotic resistance. We found that A. baumannii displays two different phenotypes specialized in host colonization and environmental persistence, respectively. The objective is to uncover how this pathogen regulates its phenotypes to spread in a host community. This objective will be pursued by using molecular genetics, single-cell fluorescence microscopy, high-throughput flow cytometry measurements of infection, and mathematical multi-scale modeling. The long-term goal of our studies is to manipulate phenotypic switching to control A. baumannii infections.

2020 Seed G	Grants continued (Award Start – 9/1/20)
Project Title:The role of macrophages in HIV transmission, persistence, and viral rebound post antiretroviral therapy interruption.Research TeamMatthew Parsons, PhD (Assistant Professor, SOM) Mirko Paiardini, PhD (Associate Professor, SOM) Janet McNicholl, MD (PI, CDC)Award Total:\$250,000 over 2 years	<u>Abstract</u> : HIV primarily infects CD4+ T-cells, but also infects macrophages. An understanding of the role of macrophages in HIV transmission and persistence will assist HIV vaccine and cure design. The proposed experiments use macaque SIV models of HIV exposure and persistence to assess the role of macrophages in HIV transmission, persistence during antiretroviral therapy (ART) and post-ART viral rebound. We will assess: (I) macrophage-mediated HIV transmission in the presence or absence of rectal syphilis; and (II) if latently infected macrophages reinitiate viral replication following ART cessation. Generated data will inform strategies to reduce HIV incidence through viral eradication and preventingtransmission.
Project Title:Fecal Microbiota Transplantation for Multi-Drug ResistantOrganism Eradication in Patients & Their Environment.Research TeamMichael Woodworth, MD (Professor, SOM)Colleen Kraft, MD (Associate Professor, SOM)Max Lau, PhD (Assistant Professor, RSPH)Award Total:\$200,000 over 2 years	<u>Abstract</u> : Antimicrobial resistance is an urgent threat with few effective treatments. Small, observational studies show that fecal microbiota transplantation (FMT) is up to 87.5% effective in eradicating multi-drug resistant organism (MDRO) colonization. FMT shows enormous potential as an approach to eradicate MDROs, but its mechanisms are poorly understood and its potential to reduce transmission have never been studied. This application builds a new collaboration between the Schools of Medicine and Public Health with a phase 1 trial of FMT for MDRO decolonization. This knowledge will serve as a springboard to understand mechanisms of FMT to interrupt MDRO transmission in populations.

2021 Seed Grants continued (Award Start – 9/1/21)

 <u>Project Title</u>: Dissecting the evolutionary dynamics of influenza A virus within and between naturally infected swine. <u>Research Team</u>: <u>Katia Koelle, PhD (Associate Professor, ECAS)</u> Anice Lowen, PhD (Associate Professor, SOM) Max Lau, PhD (Assistant Professor, RSPH) <u>Award Total</u>: \$250,000 over 2 years 	<u>Abstract</u> : Pigs play a clear role as 'mixing vessels' in influenza A virus (IAV) biology, allowing coinfection with distinct strains and subsequent genetic exchange through reassortment. Nevertheless, little is known about why pigs play this role so effectively. Examination of IAV evolution across biological scales is needed to assess whether (and how) pigs provide a context in which reassortant IAVs thrive. We propose to examine an individual outbreak in which IAVs of two subtypes spread through pigs at a week-long agricultural fair. We will characterize viral diversity and identify the evolutionary processes active at and across within-host, between-host and population levels.
 <u>Project Title</u>: Cystic fibrosis trait carrier advantage: protecting against ancient and modern epidemics. <u>Research Team</u>: Rabindra Tirouvanziam, PhD (Associate Professor, SOM) John Lindo, PhD (Assistant Professor, ECAS) Lance Waller, PhD (Professor, RSPH) Christopher LaRock, PhD (Assistant Professor, SOM) Edward Mocarski, MD, (Professor, SOM) Nael McCarty, PhD, (Professor, SOM) 	<u>Abstract</u> : Yersinia pestis and Bordetella pertussis, the agents of plague and whooping cough, respectively, carry grim records of disease and death. Here, we propose the innovative idea that both these cAMP-inducing bacteria exploit the cAMP-activated CFTR channel in host cells to flush the airway mucus and delay immune recognition. Furthermore, we propose that CFTR mutations (despite causing the fatal disease cystic fibrosis when affecting both alleles) may have been selected because they endow carriers (those with one mutated allele) with resistance to plague and pertussis. This multi-scale project will explore the broad genetic, anthropological, immunological and therapeutic implications of this idea.

Award Total: \$300,000 over 3 years

2022	2 Seed Grants (Award Start – 9/1/22)
 <u>Project Title</u>: Spillover, spillback, and evolutionary dynamics of SARS-CoV2 in white-tailed deer populations <u>Research Team</u>: Dave Civitello, PhD (Assistant Professor, ECAS) Max Lau, PhD (Assistant Professor, RSPH) <u>Award Total</u>: \$200,000 over 2 years 	<u>Abstract</u> : SARS-CoV-2 is a multi-host pathogen, yet major gaps exist in our understanding of its ecology and evolution in non- humans. Here we propose a multi-scale modeling framework that will elucidate drivers of SARS-CoV-2 ecology and evolution in white-tailed deer, which are easily infected, interact with humans in the wild and captivity, and were linked to the emergence of a novel SARS-CoV-2 variant. We will synthesize within-host infection and immunity dynamics, age- and sex- dependent sociality, seasonality, and harvest to understand the factors driving spread, persistence, and evolution of SARS- CoV-2 in deer populations and generate testable predictions for spillover and spillback to humans.

2023 See	ed Grants (Award Start – 1/1/23)
Project Title: Impact of existing chronic infection on the pathogenesis and immune responses to acute infectionResearch Team:Mohamed Abdel Hakeem, PhD (Assistant Professor, SOM)David Gordon, PhD (Assistant Professor, SOM)Heather Carleton, PhD (PI, CDC)Award Total: \$250,000 over 1.5 years	<u>Abstract</u> : Millions of people in US suffer from chronic diseases, such as cancer and chronic viral infection, that create an exhaustion state of the immune system. This pre-existing exhaustion state has a bystander effect that compromises optimal immune responses to new stimuli, including co-infections or vaccination. Additionally, these pre-existing chronic diseases could have an impact on the pathogenesis of acute pathogens, and the prevalence of specific strains circulating in the population. Thus, deeper understanding of the menage-a-trois Updated 2.7.2023 8 between the chronic pathogen, host, and acute pathogen is pivotal for rational design of tailored therapeutic and vaccination strategies for chronic patients.
Project Title: Ecology and genomics of Heartland virus (HRTV), an emerging tick-borne virus Research Team: Anne Piantadosi, MD/PhD (Assistant Professor, SOM) Gonzalo Vazquez-Prokopec, PhD (Professor, ECAS) Award Total: \$200,000 over 1.5 years	<u>Abstract</u> : Heartland virus (HRTV) is an emerging tick-borne phlebovirus that causes severe febrile illness. Little is known about its enzootic cycle. We identified an HRTV hotspot in central Georgia with positive Amblyomma americanum from 2019-2022. We will extensively sample this site to understand seasonal and stadial patterns of HRTV-positivity, and identify potential reservoir hosts. We will also survey sites with recent Haemaphysalis longicornis invasion; this tick is competent for HRTV and also a key vector of the related Dabie bandavirus, which is widespread in Asia. We thus aim to improve knowledge of HRTV before it becomes a more prominent health threat.
2024 See	ed Grants (Award Start – 6/1/23)
Project Title: Defining the impact of DENV diversity and evolution on virus spread and vaccine efficacy Research Team: Christopher Neufeldt, PhD (Assistant Professor, SOM)	<u>Abstract</u> : Dengue virus (DENV), which can result in a range of outcomes from acute illness to hemorrhagic fever and death, causes approximately 400 million yearly infections. With nearly half of the world's population at risk of DENV infection, there is an urgent and critical need for effective preventive measures. A major challenge for DENV vaccine development is the high

Christopher Neufeldt, PhD (Assistant Professor, SOM) Matthew Collins, MD/PhD (Associate Professor, SOM) Katia Koelle, PhD (Professor, ECAS)

Anne Piantadosi (Associate Professor, SOM)

Award Total: \$250,000 over 2 years

MP3 Initiative: From Molecules and Pathogens to Populations and Pandemics

molecular, individual, and population levels

genetic diversity within and between the four serotypes, which significantly impacts antibody

antigenic landscape to build a comprehensive understanding of host-pathogen interactions at

responses. Our proposed work will use innovative techniques to map the DENV genetic and

COVID-19) Cycle 1 (Award Start – 5/1/20)
Project Title:Development of 2019-nCov-specific antibodies from lampreysResearch Team:Max D. Cooper, MD (Professor, SOM)Masayuki Hirano, PhD (Assistant Professor, SOM)Balwan Singh, PhD (PI, CDC)Award Total:\$123,806 over 1 year	<u>Abstract</u> : The outbreak of a novel coronavirus (2019-nCoV, now also called severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2)) represents a pandemic threat that has been declared a public health emergency. The coronavirus Spike (S) glycoproteins (CoV S) promote infection by fusing the viral and cellular membranes. Widely available immunoglobulin-based monoclonal antibodies (mAbs), which are specific to SARS-CoV S, do not bind to 2019-nCoV S, suggesting antibody cross- reactivity may be limited. We will generate lamprey mAbs, which are composed of Leucine-rich repeat modules, with exquisite specificity for 2019-nCoV S.
Project Title: Landscape of coronavirus recombination across scalesResearch Team:Anice Lowen, PhD (Associate Professor, SOM)Mehul Suthar, PhD (Assistant Professor, SOM)Katia Koelle, PhD (Associate Professor, ECAS)Award Total:\$150,000 over 1 year	<u>Abstract</u> : Recombination of coronavirus genomes has been observed both in vitro and in naturally circulating viruses. This type of genetic exchange can have major implications at the population level because genetic diversity generated during this exchange expands viral adaptive potential. With the goal of anticipating epidemiologically significant recombination events involving SARS-CoV-2, we will use experimental, modeling, and phylogenetic analysis approaches to quantitatively examine recombination of human coronaviruses at cellular and population level scales. By integrating our findings across these scales, our overall objective is to identify genomic signatures of recombination that are likely to be adaptive for this family of viruses.
Project Title:SARS-COV-2 pathogenesis, immune responses, and treatment:from macaques to humansResearch Team:Mirko Paiardini, PhD (Associate Professor; ENPRI/SOM)Anne Piantadosi, MD, PhD (Assistant Professor, SOM)Raymond Schinazi, PhD (Professor, SOM)Award Total:\$150,000 over 1 year	<u>Abstract</u> : This project leverages a novel model of SARS-CoV-2 infection to characterize the immune response to the virus; define the main anatomical sites and kinetics of viral replication and evolution; and test novel strategies targeted at SARS- CoV-2 that could be directly translatable to the clinic. These analyses will be performed utilizing a cross-scales approach, from cellular and molecular immunology to whole-host analysis. Simultaneously, the non-human primate data will be coupled with data generated from human specimens to understand intrahost and population level viral evolution. These results will be integrated to generate novel insights to inform the direct care of infected individuals.

COVID-19 Cycle 2 (Award Start - 9/1/20)

Project Title: Structure, function, and rational inhibitor design of the SARS-	Abstract: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has created a
CoV-2 RNA polymerase.	global health threat, and no vaccines or therapeutic agents are available. Viral polymerases
<u>Research Team</u> : Bo Liang (Assistant Professor, SOM) Baek Kim (Professor, SOM) Dennis Liotta (Professor, ECAS)	have been major anti-viral therapeutic targets, as seen in multiple drug discovery successes. Drug design relies heavily on obtaining accurate structural and functional analysis. We will use existing, as well as our newly generated structural data to rationally design novel inhibitors optimized for the SARS-CoV-2polymerase.

Award Total: \$150,000 over 1 year

COVID-19 Cycle 3	(CURE co-fund; Award Start – 3/1/21)
Project Title:Estimating the cumulative incidence of SARS-CoV-2 infection in50 U.S. states to inform COVID-19 vaccine evaluation.Research Team:Benjamin Lopman, PhD (Professor, RSPH)Kayoko Shioda, DVM/PhD (Staff Scientist, RSPH)Mannish Patel, (PI, CDC)Matthew Collins, MD/PhD (Associate Professor, SOM)Award Total:\$50,000 over 1 year	Abstract: To understand and control the COVID-19 pandemic, we need to reliably estimate the true number of infections, i.e. the cumulative incidence. Although serology tests can identify previous infections, immunoglobulins targeting SARS-CoV-2 wane below the detectable level of serological assays over time, likely leading to underestimation of cumulative incidence. Therefore, our multidisciplinary team of Emory investigators, in collaboration with CDC, will estimate the cumulative incidence from longitudinal seroprevalence data, accounting for antibody waning. We will then estimate how the total effectiveness of COVID-19 vaccines varies depending on the baseline cumulative incidence (an estimate of population immunity) across states.
Project Title:Assessing breadth of infection- and vaccine-elicited immunity against emergent SARS-CoV-2 variants.Research Team:Erin Scherer, PhD (Assistant Professor, SOM) Nadine Rouphael, MD (Professor, SOM)Award Total:\$50,000 over 1 year	Abstract: Three SARS-CoV-2 variants have emerged: B.1.351, B.1.1.7, and P.1. B.1.351 and B.1.1.7 are concerning because they have mutations in neutralizing antibody epitopes and are resistant to neutralization by convalescent plasma and vaccinee antibodies. We aim to determine whether P.1 is resistant to pre-variant COVID-19 patient and vaccinee antibody recognition to understand SARS-CoV-2 epitopes under selection pressure and help guide vaccine design. We also aim to assess whether memory B cells and memory helper T cells in pre-variant COVID-19 patients or vaccinees recognize variants to understand if they may play a role in the control of viral variants and disease prevention/attenuation.

Synergy II Nexus Award (co-fund) Award Start – 9/1/21

Project Title:Mapping the eco-evolutionary landscape of antibiotic resistanceAbstract:and virulence in the bacterialpathogen Staphylococcus aureus.sequence

Research Team:

Daniel Weissman, PhD (Assistant Professor, ECAS) Tim Read, PhD (Professor SOM) <u>Abstract</u>: Staphylococcus aureus is a major antibiotic-resistant human pathogen. Public sequence efforts have produced > 70,000 genome sequences and it is present in many thousands of microbiome samples. We will combine the PI's expertise in population biology and the co-PI's expertise in microbial bioinformatics to develop novel analytic approaches to find genetic interactions related to the evolution of antibiotic resistance and test whether these interactions are mediated by environmental context.

Award Total: \$50,000 over 1 year

Faculty Startup Packages (Award Start – varies)	
Matthew Gardner, PhD	Latania Logan, MD
Medicine, SOM	Pediatrics, SOM
(Award Date 2020)	(Award Date 2021)
Elizabeth Rogawski McQuade, PhD	David E. Gordon, PhD
Epidemiology, RSPH	Pathology and Laboratory Medicine, SOM
(Award Date 2020)	(Award Date 2021)
Natalie Dean, PhD	Christopher Neufeldt, PhD
Biostatistics and Informatics (Jointly Appointed, Epidemiology), RSPH	Microbiology and Immunology, SOM
(Award Date 2021)	(Award Date 2021)
Micaela Martinez, PhD	Maya Nadimpalli, PhD
Biology, ECAS	Environmental Health, (Jointly Appointed, Global Health and Epidemiology), RSPH
(Award Date 2021)	(Award Date 2021)